Bristol-Myers Squibb will move straight to the appeals stage in paclitaxel patent litigation with Ivax and other generic co-defendants, rather than go to trial over the patent claims remaining after a March 2 Newark, N.J. federal court decision of partial summary judgement. The appeal will focus on the patent claims dismissed by the decision, which invalidated the non-ovarian cancer claims. The decision also cleared the way for Ivax to launch its generic paclitaxel for breast cancer once its application is approved by FDA following the expiration of the 30-month Waxman/Hatch stay of approval in June (1"The Pink Sheet" March 6, p. 25)
You may also be interested in...
Ivax plans to launch a generic version of Bristol-Myers Squibb's Taxol (paclitaxel) without waiting for Bristol to appeal a Newark, N.J. federal court summary judgment that deems the majority of Bristol's paclitaxel patent claims invalid.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials